<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01745263</url>
  </required_header>
  <id_info>
    <org_study_id>KEK-ZH-2012-0249</org_study_id>
    <secondary_id>DO-HEALTH</secondary_id>
    <nct_id>NCT01745263</nct_id>
  </id_info>
  <brief_title>DO-HEALTH / Vitamin D3 - Omega3 - Home Exercise - Healthy Ageing and Longevity Trial</brief_title>
  <acronym>DO-HEALTH</acronym>
  <official_title>Vitamin D3 - Omega3 - Home Exercise - Healthy Ageing and Longevity Trial (Acronym: DO-HEALTH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Recruitment Partners</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Geneva, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Basel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Toulouse, France (Prof. Bruno Vellas, MD)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Coimbra, Portugal (Prof. José daSilva, MD)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Other University Partners</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sheffield</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Manchester, UK (Prof. David Felson, MD MPH)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Max Rubner University, Germany (Prof. Bernhard Watzl, PhD)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Impact Partner</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Osteoporosis Foundation (IOF; Prof. John Kanis, MD)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SME Partners</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ferrari Data Solutions GmBH, Switzerland (Stephen M. Ferrari; direct data entry platform)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gut Pictures, Switzerland (Benno Gut; animated exercise video)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NOVAMEN, France (Sandrine Rival; logistic management partner)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharmalys, UK (Marieme Ba; monitoring partner)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Industry Partners</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>DSM Nutritional Products (Dr. Elisabeth Stöcklin PhD, Dr. Manfred Eggersdorfer PhD)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nestlé (Michaela Höhne PhD, Irène Corthesy PhD)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Diagnostics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Funding within Framework 7 research program of the European Commission (project 278588)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Further collaborators and advisors at website do-health.eu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The European population is aging rapidly which poses a challenge on the individual, the
      European societies, and health care systems. Among the most promising public health
      interventions that may extend healthy life expectancy at older age are vitamin D, marine
      omega-3 fatty acids and physical exercise. However, their individual and combined effects
      have yet to be confirmed in a clinical trial.

      The broad aim of DO-HEALTH is to prolong healthy life expectancy in European seniors. The
      specific aim is to establish whether vitamin D, omega-3 fatty acids, and a simple home
      exercise program will prevent disease at older age.

      To achieve these aims, DO-HEALTH will enroll 2152 community-dwelling men and women who are 70
      years and older, an age when chronic diseases increase substantially. The DO-HEALTH seniors
      will be recruited from 7 European cities (Zurich, Basel, Geneva, Toulouse, Berlin, Innsbruck
      and Coimbra) and will be randomized in a 2x2x2 factorial design trial to a simple home
      exercise program and/or vitamin D, and/or omega-3 fatty acids, over a 3 year period. This
      will allow to test the individual and the combined benefit of the interventions in the
      prevention of 5 primary endpoints: the risk of incident non-vertebral fractures; the risk of
      functional decline; the risk of blood pressure increase; the risk of cognitive decline; and
      the rate of any infection. Key secondary endpoints include risk of hip fracture, rate of
      falls, pain in symptomatic knee osteoarthritis, gastro-intestinal symptoms, mental and oral
      health, quality of life, and life-expectancy.

      All clinical endpoints will be supported by a large DO-HEALTH biomarker study to evaluate the
      effect of the interventions at the cellular level of multi-organ function. DO-HEALTH will
      further evaluate reasons why or why not seniors adhere to the 3 interventions, and will
      assess their cost-benefit in a health economic model based on documented health care
      utilization and observed incidence of chronic disease.

      website DO-HEALTH: http://do-health.eu/wordpress/ website EC:
      http://ec.europa.eu/research/health/medical-research/human-development-and-ageing/projects/do
      -health_en.html
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The 3 primary treatment comparisons are:

        1. 2000 IU vitamin D per day compared to placebo (controlling for the other treatment
           strategies)

        2. 1 gram of omega-3 fatty acids (EPA+DHA, ratio 1:2, from marine algae) compared to
           placebo (controlling for the other treatment strategies)

        3. Home exercise program (muscle strength) of 30 minutes 3 times a week compared to a
           control exercise program (joint flexibility) 30 minutes 3 times a week

      Follow-up: DO-HEALTH seniors will be followed for 3 years, in-person, and in 3-monthly
      intervals (4 clinical visits and 9 phone calls) at the 7 recruitment centers.

      Study population: DO-HEALTH will enroll seniors age 70 years and older. To represent the
      largest part of the senior population, DO-HEALTH will recruit community-dwelling seniors.
      However, to represent also the pre-frail population at risk of institutionalization, 50% of
      seniors will be enrolled based on a fall with or without a fracture in the year before
      DO-HEALTH enrolment.

      Study Design: This is a randomized, double-blind, placebo-controlled, 2×2×2 factorial design
      clinical trial.

      Recruitment Centers: The trial will be performed at 7 recruitment centers located in 5
      countries: Switzerland (University of Zurich, Basel University Hospital, Geneva University
      Hospital), France (University of Toulouse Hospital Centre), Germany (Charité Berlin),
      Portugal (University of Coimbra), and Austria (Innsbruck Medical University).

      Randomization: Stratified block randomization. Labeling of study intervention will be
      performed by a central randomization centre in Switzerland.

      Stratification variables: recruitment centre (7 centers), fall during previous 12 months
      (yes/no), gender, and age (70 - 84 and 85+). Even balance among those who fell or did not
      fall during the last year will be enforced at each of the 7 recruitment centers. Gender and
      age distribution will be monitored within each recruitment centre with the DO-HEALTH
      randomization software. If gross imbalance (less than 30% of participants in a stratum) is
      detected within a centre, recruitment strategies for the centre will be adapted to boost
      recruitment of participants of underrepresented category.

      website DO-HEALTH: http://do-health.eu/wordpress/ website EC:
      http://ec.europa.eu/research/health/medical-research/human-development-and-ageing/projects/do
      -health_en.html
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 20, 2012</start_date>
  <completion_date type="Actual">January 19, 2018</completion_date>
  <primary_completion_date type="Actual">November 17, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone: Incident non-vertebral fractures</measure>
    <time_frame>36 months</time_frame>
    <description>Confirmed by medical and/or x-ray reports</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle: Functional decline (lower extremity function)</measure>
    <time_frame>Baseline, 12, 24 and 36 months</time_frame>
    <description>Measured with the SPPB (short physical performance test battery)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardio-vascular: Systolic and diastolic blood pressure change</measure>
    <time_frame>Baseline, 12, 24 and 36 months</time_frame>
    <description>Standardized blood pressure assessment in sitting position</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain: Cognitive decline</measure>
    <time_frame>Baseline, 12, 24 and 36 months</time_frame>
    <description>Montreal Cognitive Assessment (MoCA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunity: Rate of infections</measure>
    <time_frame>Baseline, and every 3 months up to 36 months</time_frame>
    <description>3-monthly incident infection protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone: Incident hip fractures</measure>
    <time_frame>36 months</time_frame>
    <description>Based on medical records and/or x-ray reports</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone: Incident total fractures</measure>
    <time_frame>36 months</time_frame>
    <description>Combined non-vertebral and vertebral fractures among subgroup of 1502 participants with DXA vertebral morphometry assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone: Incident vertebral fractures</measure>
    <time_frame>36 months</time_frame>
    <description>Based on DXA vertebral morphometry among subset of 1502 participants with DXA measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone: Bone mineral density decrease at the lumbar spine and hip</measure>
    <time_frame>Baseline, 12, 24, and 36 months</time_frame>
    <description>Assessed in a subset of 1502 participants with DXA measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle: Rate of falls</measure>
    <time_frame>Assessed every 3 months over 36 months</time_frame>
    <description>Any low trauma fall, injurious fall, faller</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle: reaction time and grip strength</measure>
    <time_frame>Baseline, 12,24,36 months</time_frame>
    <description>Reaction time will be assessed with the repeated sit-to-stand test; grip strength will be assessed with the Martin Vigorimeter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle: Muscle mass decrease at upper and lower extremities</measure>
    <time_frame>Baseline, 12,24,36 months</time_frame>
    <description>Subset of 1502 participants with DXA measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle: Dual tasking 10-meter gait speed</measure>
    <time_frame>Baseline, 12,24 and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle/Bone: musculoskeletal pain</measure>
    <time_frame>Baseline, 12,24, and 36 months</time_frame>
    <description>Assessed with the McGill questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardio-vascular: Incident Hypertension</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain: mental health decline</measure>
    <time_frame>Baseline, 12,24, and 36 months</time_frame>
    <description>Assessed with Geriatric Depression Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain: Incident Depression</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain/Muscle: Dual tasking gait variability</measure>
    <time_frame>Baseline, 12, 24 and 36 months</time_frame>
    <description>Subset of 250 participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunity: Rate of upper respiratory infections / rate of flu-like illness</measure>
    <time_frame>36 months</time_frame>
    <description>Assessed with infection protocol every 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunity: Incident severe infections that lead to hospital admission</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cartilage/Bone: Severity of knee pain in participants with symptomatic knee osteoarthritis</measure>
    <time_frame>Baseline, 12, 24 and 36 months</time_frame>
    <description>Assessed with the KOOS questionnaire. Knee OA assessment with modified ACR criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cartilage/Bone: Rate of knee buckling</measure>
    <time_frame>Baseline, 12,24,36 months</time_frame>
    <description>Questionnaire-based.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cartilage/Bone: NSAID use / number of joints with pain</measure>
    <time_frame>Baseline, 12, 24, 36 months</time_frame>
    <description>Assessed by questionnaire and homunculus figure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dental: Decline in oral health</measure>
    <time_frame>Baseline, 12,24 and 36 months</time_frame>
    <description>Assessed with questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dental: Tooth loss</measure>
    <time_frame>36 months</time_frame>
    <description>Assessed by tooth count at every clinical visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastro-Intestinal: rate of GI symptoms</measure>
    <time_frame>Baseline, 12, 24 and 36 months</time_frame>
    <description>Assessed with ROME III questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose-Metabolic: Change in fasting glucose, insulin levels (QUICKI, HOMA index)</measure>
    <time_frame>Baseline, 12,24,36 months</time_frame>
    <description>Laboratory measures at the Central DO-HEALTH Laboratory (Institute of Clinical Chemistry at the University Hospital Zurich)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose-Metabolic: Body composition</measure>
    <time_frame>Baseline, 12, 24, 36 months</time_frame>
    <description>Subset of 1502 participants with DXA measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney: Decline in kidney function</measure>
    <time_frame>Baseline, 12, 24, and 36 months</time_frame>
    <description>Blood creatinine levels and estimated glomerular filtration rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Health: Quality of life</measure>
    <time_frame>Every 6 months</time_frame>
    <description>Assessed with questionnaire (EuroQuol).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Health: Incident disability regarding activities of daily living</measure>
    <time_frame>Baseline, 12, 24 and 36 months</time_frame>
    <description>Assessed with HAQ-PROMIS questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Health: Incident nursing home admission</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Health: Mortality</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Large organ-specific biomarker study</measure>
    <time_frame>Baseline, 12, 24, and 36 months</time_frame>
    <description>See http://do-health.eu/wordpress/</description>
  </other_outcome>
  <other_outcome>
    <measure>Bone: Incident repeat fractures</measure>
    <time_frame>36 months</time_frame>
    <description>Any repeat non-vertebral fractures in all participants, vertebral fractures and total fractures among subset of 1502 seniors with yearly DXA measurements</description>
  </other_outcome>
  <other_outcome>
    <measure>BONE: Functional recovery after fracture</measure>
    <time_frame>36 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Muscle: Incident sarcopenia / incident frailty / decline in physical function</measure>
    <time_frame>36 months</time_frame>
    <description>Incident sarcopenia (among subset of 1502 seniors with yearly DXA measurements), incident frailty (questionnaire), decline in physical activity (questionnaire)</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardio-vascular: Major cardio-vascular events</measure>
    <time_frame>36 months</time_frame>
    <description>Major cardiovascular events as a composite endpoint (any event: myocardial infarction, stroke, revascularization procedures of CABG and PCI, incident congestive heart disease, cardiovascular mortality); individual endpoints: myocardial infarction, stroke, incident congestive heart disease, and cardiovascular mortality (assessed every 3 months over 36 months)</description>
  </other_outcome>
  <other_outcome>
    <measure>Brain: incident dementia</measure>
    <time_frame>36 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Immunity: Incident cancer / rate of implant infections / rate of gastro-intestinal infections</measure>
    <time_frame>36 months</time_frame>
    <description>Incident cancer (any cancer, gastro-intestinal, breast cancer in women, prostate cancer in men); rate of implant infections after total hip or knee replacement (due to fracture or osteoarthritis); rate of gastro-intestinal infections</description>
  </other_outcome>
  <other_outcome>
    <measure>Cartilage/bone: Incident osteoarthritis</measure>
    <time_frame>Baseline, 12, 24, and 36 months</time_frame>
    <description>Incident symptomatic knee osteoarthritis; incident symptomatic hip osteoarthritis, incident symptomatic hand osteoarthritis; composite endpoint: incident symptomatic knee, hip or hand osteoarthritis; severity of hip pain in those with prevalent symptomatic hip osteoarthritis, severity of hand pain in those with prevalent symptomatic hand osteoarthritis</description>
  </other_outcome>
  <other_outcome>
    <measure>Adherence laboratory</measure>
    <time_frame>Baseline, 12, 24, and 36 months</time_frame>
    <description>Serum 25(OH)D concentrations (measured both by an automated assay and HPLCMS/MS) and plasma PUFA concentrations (EPA, AA, DPA, DHA; measured by a sensitive and selective assay based on gas chromatography coupled to mass spectrometry detection (GC-MS)) in all participants</description>
  </other_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">2159</enrollment>
  <condition>Improve Healthy Ageing in Seniors; Prevent Disease at Older Age</condition>
  <arm_group>
    <arm_group_label>VitD-Omega3-StrengthExercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D3 (2000 IU/d); Omega-3 fatty acids (1 g/d); Strength Home Exercise (3*30 minutes/week)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VitD-Omega3-FlexibilityExercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D3 (2000 IU/d); Omega-3 fatty acids (1 g/d); Flexibility Home Exercise (3*30 minutes/week)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Omega3-StrengthExercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo Vitamin D3; Omega-3 fatty acids (1 g/d); Strength Home Exercise (3*30 minutes/week)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Omega3-FlexibilityExercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo Vitamin D3; Omega-3 fatty acids (1 g/d); Flexibility Home Exercise (3*30 minutes/week)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VitD-Placebo-StrengthExercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D3 (2000 IU/d); Placebo Omega-3 fatty acids; Strength Home Exercise (3*30 minutes/week)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VitD-Placebo-FlexiblityExercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D3 (2000 IU/d); Placebo Omega-3 fatty acids; Flexibility Home Exercise (3*30 minutes/week)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Placebo-StrengthExercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo Vitamin D3; Placebo Omega-3 fatty acids; Strength Home Exercise (3*30 minutes/week)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Placebo-FlexibilityExercise</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Placebo Vitamin D3; Placebo Omega-3 fatty acids; Flexibility Home Exercise (3*30 minutes/week)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>2000 IU/d</description>
    <arm_group_label>VitD-Omega3-StrengthExercise</arm_group_label>
    <arm_group_label>VitD-Omega3-FlexibilityExercise</arm_group_label>
    <arm_group_label>VitD-Placebo-StrengthExercise</arm_group_label>
    <arm_group_label>VitD-Placebo-FlexiblityExercise</arm_group_label>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega 3 fatty acids</intervention_name>
    <description>Ratio EPA:DHA = 1:2
1 g/d</description>
    <arm_group_label>VitD-Omega3-StrengthExercise</arm_group_label>
    <arm_group_label>VitD-Omega3-FlexibilityExercise</arm_group_label>
    <arm_group_label>Placebo-Omega3-StrengthExercise</arm_group_label>
    <arm_group_label>Placebo-Omega3-FlexibilityExercise</arm_group_label>
    <other_name>Eicosapentaenoic acid AND Docosahexaenoic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Strength Home Exercise</intervention_name>
    <arm_group_label>VitD-Omega3-StrengthExercise</arm_group_label>
    <arm_group_label>Placebo-Omega3-StrengthExercise</arm_group_label>
    <arm_group_label>VitD-Placebo-StrengthExercise</arm_group_label>
    <arm_group_label>Placebo-Placebo-StrengthExercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Flexibility Home Exercise</intervention_name>
    <arm_group_label>VitD-Omega3-FlexibilityExercise</arm_group_label>
    <arm_group_label>Placebo-Omega3-FlexibilityExercise</arm_group_label>
    <arm_group_label>VitD-Placebo-FlexiblityExercise</arm_group_label>
    <arm_group_label>Placebo-Placebo-FlexibilityExercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Age 70 years or older

          -  Mini Mental State Examination Score of at least 24

          -  Living in the community

          -  Sufficiently mobile to come to the study centre

          -  Able to walk 10 meters with or without a walking aid and able to get in and out of a
             chair without help

          -  Able to swallow study capsules

          -  Able and willing to participate, sign informed consent (including consent to analyze
             all samples until drop-out or withdrawal) and cooperate with study procedures

        Exclusion criteria:

          -  Consumption of more than 1000 IU vitamin D/day in the 36 months prior to enrollment,
             or a bolus of 300'000 IU or more in the last 12 month prior to enrollment, and/ or
             unwillingness to limit vitamin D intake to the current standard of 800 IU/day of
             vitamin D during the course of the trial. Provision 1: an individual who consumed an
             average vitamin D dose between 1000 and 2000 IU vitamin D/day in the 3 months prior to
             enrollment, may be enrolled after a 3-month wash-out period where the maximum daily
             intake is limited to 800 IU vitamin D. Provision 2: an individual who consumed an
             average vitamin D dose higher than 2000 IU/day in the 3 months prior to enrollment,
             may be enrolled after a 6-month wash-out period where the maximum daily intake is
             limited to 800 IU vitamin D.

          -  Unwillingness to limit calcium supplement dose to 500 mg per day for the duration of
             the trial

          -  Taking omega-3 fat supplements in the 3 month prior to enrolment and unwilling to
             forgo their use for the duration of the trial

          -  Use of any active vitamin D metabolite (i.e. Rocaltrol, alphacalcidiol), PTH treatment
             (i.e. Teriparatide), or Calcitonin at baseline and unwillingness to forego these
             treatments during the course of the trial

          -  Current or recent (previous 4 months) participation in another clinical trial, or
             plans of such participation in the next 3 years (corresponding to DO-HEALTH length)

          -  Presence of the following diagnosed health conditions in the last 5 years: history of
             cancer (except non-melanoma skin cancer); myocardial infarction, stroke, transient
             ischemic attack, angina pectoris, or coronary artery intervention

          -  Severe renal impairment (creatinine clearance = 15 ml/min) or dialysis, hypercalcaemia
             (&gt; 2.6 mmol/l)

          -  Hemiplegia or other severe gait impairment

          -  History of hypo- or primary hyperparathyroidism

          -  Severe liver disease

          -  History of granulomatous diseases (i.e. tuberculosis, sarcoidosis)

          -  Major visual or hearing impairment or other serious illness that would preclude
             participation

          -  Living with a partner who is enrolled in DO-HEALTH (i.e. only one person per household
             can be enrolled)

          -  Living in assisted living situations or a nursing home

          -  Temporary exclusion: acute fracture in the last 6 weeks

          -  Epilepsy and/or use of anti-epileptic drugs

          -  Individuals who fell more than 3 times in the last month

          -  Osteodystrophia deformans (M. Paget, Paget's disease)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heike Bischoff Ferrari, Prof MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>&quot;Centre on Aging and Mobility&quot; University of Zurich, University Hospital Zurich and City Hospital Waid.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toulouse - Centre de Recherche - Gérontopôle Hôpital La Grave</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Coimbra - Clínica Universitária de Reumatologia</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre on Aging and Mobility, University of Zurich and City Hospital Waid</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Basel University</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Genève</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Portugal</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://do-health.eu</url>
    <description>Website DO-HEALTH Consortium</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2012</study_first_submitted>
  <study_first_submitted_qc>December 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2012</study_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Zurich</investigator_affiliation>
    <investigator_full_name>Heike Bischoff-Ferrari</investigator_full_name>
    <investigator_title>Director, Centre on Aging and Mobility</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

